These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9802625)

  • 1. Age-related immunogenicity of meningococcal polysaccharide vaccine in aboriginal children and adolescents living in a Northern Manitoba reserve community.
    Law BJ; Rosenberg T; MacDonald NE; Ashton FE; Huang JC; King WJ; Ferris WJ; Gray GJ
    Pediatr Infect Dis J; 1998 Oct; 17(10):860-4. PubMed ID: 9802625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.
    King WJ; MacDonald NE; Wells G; Huang J; Allen U; Chan F; Ferris W; Diaz-Mitoma F; Ashton F
    J Pediatr; 1996 Feb; 128(2):196-202. PubMed ID: 8636811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
    MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
    JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.
    MacLennan JM; Shackley F; Heath PT; Deeks JJ; Flamank C; Herbert M; Griffiths H; Hatzmann E; Goilav C; Moxon ER
    JAMA; 2000 Jun; 283(21):2795-801. PubMed ID: 10838647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.
    Maslanka SE; Tappero JW; Plikaytis BD; Brumberg RS; Dykes JK; Gheesling LL; Donaldson KB; Schuchat A; Pullman J; Jones M; Bushmaker J; Carlone GM
    Infect Immun; 1998 Jun; 66(6):2453-9. PubMed ID: 9596702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
    Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA
    JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
    Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.
    Maslanka SE; Gheesling LL; Libutti DE; Donaldson KB; Harakeh HS; Dykes JK; Arhin FF; Devi SJ; Frasch CE; Huang JC; Kriz-Kuzemenska P; Lemmon RD; Lorange M; Peeters CC; Quataert S; Tai JY; Carlone GM
    Clin Diagn Lab Immunol; 1997 Mar; 4(2):156-67. PubMed ID: 9067649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.
    Al-Mazrou Y; Khalil M; Borrow R; Balmer P; Bramwell J; Lal G; Andrews N; Al-Jeffri M
    Infect Immun; 2005 May; 73(5):2932-9. PubMed ID: 15845499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.
    Pichichero M; Casey J; Blatter M; Rothstein E; Ryall R; Bybel M; Gilmet G; Papa T
    Pediatr Infect Dis J; 2005 Jan; 24(1):57-62. PubMed ID: 15665711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; De Serres G; Niyonsenga T
    JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.
    Borrow R; Richmond P; Kaczmarski EB; Iverson A; Martin SL; Findlow J; Acuna M; Longworth E; O'Connor R; Paul J; Miller E
    FEMS Immunol Med Microbiol; 2000 May; 28(1):79-85. PubMed ID: 10767611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.
    Milagres LG; Ramos SR; Sacchi CT; Melles CE; Vieira VS; Sato H; Brito GS; Moraes JC; Frasch CE
    Infect Immun; 1994 Oct; 62(10):4419-24. PubMed ID: 7927704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of meningococcal vaccine and barriers to vaccination.
    Rosenstein N; Levine O; Taylor JP; Evans D; Plikaytis BD; Wenger JD; Perkins BA
    JAMA; 1998 Feb; 279(6):435-9. PubMed ID: 9466635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.